Thomas Jefferson University

Jefferson Digital Commons
Cardeza Foundation for Hematologic Research

Sidney Kimmel Medical College

12-16-2019

Treatment of dental complications in sickle cell disease.
Priti Mulimani
University of Washington

Samir K. Ballas
Thomas Jefferson University

Adinegara Bl Abas
Melaka-Manipal Medical College

Laxminarayan Karanth
Melaka-Manipal Medical College

Follow this and additional works at: https://jdc.jefferson.edu/cardeza_foundation
Part of the Hematology Commons

Let us know how access to this document benefits you
Recommended Citation
Mulimani, Priti; Ballas, Samir K.; Abas, Adinegara Bl; and Karanth, Laxminarayan, "Treatment of
dental complications in sickle cell disease." (2019). Cardeza Foundation for Hematologic
Research. Paper 57.
https://jdc.jefferson.edu/cardeza_foundation/57
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Cardeza Foundation for Hematologic Research by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Cochrane
Library
Cochrane Database of Systematic Reviews

Treatment of dental complications in sickle cell disease (Review)
Mulimani P, Ballas SK, Abas ABL, Karanth L

Mulimani P, Ballas SK, Abas ABL, Karanth L.
Treatment of dental complications in sickle cell disease.
Cochrane Database of Systematic Reviews 2019, Issue 12. Art. No.: CD011633.
DOI: 10.1002/14651858.CD011633.pub3.

www.cochranelibrary.com

Treatment of dental complications in sickle cell disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

TABLE OF CONTENTS
HEADER.........................................................................................................................................................................................................
ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
WHAT'S NEW.................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

Treatment of dental complications in sickle cell disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
1
2
3
4
4
8
8
9
9
10
12
14
14
14
15
15

i

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

[Intervention Review]

Treatment of dental complications in sickle cell disease
Priti Mulimani1, Samir K Ballas2, Adinegara BL Abas3, Laxminarayan Karanth4
1Oral Health Sciences, School of Dentistry, University of Washington, Seattle, WA, USA. 2Cardeza Foundation for Hematologic Research,

Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA. 3Department of Community
Medicine, Melaka-Manipal Medical College (Manipal Academy of Higher Education), Melaka, Malaysia. 4Department of Obstetrics and
Gynaecology, Melaka-Manipal Medical College, Manipal Academy of Higher Education (MAHE), Melaka, Malaysia

Contact address: Priti Mulimani, Oral Health Sciences, School of Dentistry, University of Washington, 1959 Pacific Street NE, Seattle, WA,
98195, USA. mulimanipriti@gmail.com.
Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 12, 2019.
Citation: Mulimani P, Ballas SK, Abas ABL, Karanth L. Treatment of dental complications in sickle cell disease. Cochrane Database of
Systematic Reviews 2019, Issue 12. Art. No.: CD011633. DOI: 10.1002/14651858.CD011633.pub3.
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT
Background
Sickle cell disease is the most common single gene disorder and the commonest haemoglobinopathy found with high prevalence in many
populations across the world. Management of dental complications in people with sickle cell disease requires special consideration for
three main reasons. Firstly, dental and oral tissues are affected by the blood disorder resulting in several oro-facial abnormalities. Secondly,
living with a haemoglobinopathy and coping with its associated serious consequences may result in individuals neglecting their oral health
care. Finally, the treatment of these oral complications must be adapted to the systemic condition and special needs of these individuals,
in order not to exacerbate or deteriorate their general health.
Guidelines for the treatment of dental complications in this population who require special care are unclear and even unavailable in many
aspects. Hence this review was undertaken to provide a basis for clinical care by investigating and analysing the existing evidence in the
literature for the treatment of dental complications in people with sickle cell disease. This is an update of a previously published review.
Objectives
To assess methods of treating dental complications in people with sickle cell disease.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Review Group's Haemoglobinopathies Trials Register, compiled from
electronic database searches and handsearching of journals and conference abstract books.
Date of last search: 01 August 2019.
Additionally, we searched nine online databases (PubMed, Google Scholar, ClinicalTrials.gov, WHO International Clinical Trials Registry
Platform, Literature in the Health Sciences in Latin America and the Caribbean database, African Index Medicus, Index Medicus for South
East Asia Region, Index Medicus for the Eastern Mediterranean Region, Indexing of Indian Medical Journals). We also searched the reference
lists of relevant articles and reviews and contacted haematologists, experts in fields of dentistry, organizations, pharmaceutical companies
and researchers working in this field.
Date of last search: 07 November 2019.
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Selection criteria
We searched for published or unpublished randomised controlled studies of treatments for dental complications in people with sickle cell
disease.
Data collection and analysis
Two review authors intended to independently extract data and assess the risk of bias of the included studies using standard Cochrane
methodologies; however, no studies were identified for inclusion in the review.
Main results
No randomised controlled studies were identified.
Authors' conclusions
This Cochrane Review did not identify any randomised controlled studies assessing interventions for the treatment of dental complications
in people with sickle cell disease. There is an important need for randomised controlled studies in this area, so as to identify the most
effective and safe method for treating dental complications in people with sickle cell disease.

PLAIN LANGUAGE SUMMARY
Treatment of dental complications in sickle cell disease
Review question
We planned to review the evidence regarding the treatment of dental complications in people with sickle cell disease.
Background
Sickle cell disease is a blood disorder which affects at least 5.2% of the world population across a large number of countries. In this
condition, a genetic defect means that the haemoglobin in the red blood cells is not normal, instead the blood cells become sickle-shaped
and not a normal disc shape. These cells become trapped in blood vessels of various organs, especially during stressful events like a lack of
oxygen, dehydration, extreme temperatures, stress, menstruation and infection. Blocked blood vessels lead to sudden episodes of severe
pain in the short term and chronic organ damage in the long term.
Sickle cell disease also leads to changes and complications in the mouth, jaw and facial areas. Management of these dental complications
is often neglected as people with sickle cell disease focus all their energy on maintaining their general health due to the serious blood
disorder. Neglecting minor dental health issues under these circumstances not only worsens the problem but may also cause a painful
sickle-cell crisis, leading to emergency hospital admissions. Treatment of oral complications in this group of people needs to be tailored
around their blood disorder, in order not to cause any further deterioration to their general health.
There is a lack of information on the appropriate treatment for dental complications in people with sickle cell disease,with no clear
guidelines available. This often results in many people being refused treatment by dentists due to a fear of complications. Hence, we
planned to investigate this issue and make any evidence in this area available to healthcare providers and people with the disease.
Search date
The evidence is current to: 01 August 2019.
Study characteristics
We were not able to find any randomised controlled studies assessing treatment for any dental complications in people with sickle cell
disease.
Key results
No studies were identified, so we can not draw any conclusions or highlight any implications for practice. Studies are needed to establish
the best treatment for dental problems in people with sickle cell disease.
Quality of the evidence
There is no evidence from studies (where people are given one treatment or another completely at random) for any treatment for dental
complications in people with sickle cell disease.
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BACKGROUND
For an explanation of terms, please refer to the glossary (Appendix
1).

Description of the condition
Problems in oral and dental health commonly experienced by
most individuals result from chronic, degenerative, pathological
changes accompanied by intermittent, recurrent, acute episodes
in dental tissues and supporting structures. As dental health
problems are not life-threatening, both individuals and non-oral
healthcare providers consider these a minor inconvenience and
the changes in behaviour required to deal with them as trivial.
Fear of dental treatment and the expense which treatment incurs
play a further inhibitory role among those seeking treatment for
dental complications. In turn, this has significant social, functional
and economic costs as seen in the 1981 National Health Interview
Survey in the USA, where 4.87 million dental conditions caused 17.7
million days of restricted activity, 6.73 million days of bed disability,
and 7.05 million days of work loss (Reisine 1985). People dealing
with more pressing and life-threatening medical conditions, such
as haemoglobinopathies, may not regard oral health as a priority
and in some cases may completely neglect it, especially those
from low socio-economic status groups. This often results in such
people arriving in hospital emergency departments with dental
complications and may warrant further hospital admission to
manage associated complications (Laurence 2013).
Haemoglobinopathies are a group of autosomal recessive
disorders affecting the structure and synthesis of haemoglobin.
Mutations in the genes of these chains give rise to conditions
such as sickle cell disease (SCD) and the thalassaemias. This
review will focus on SCD which is one of the most common
haemoglobin disorders as well as one of the most common
single-gene disorders in the world (Colledge 2010; Fonseca 2007).
Haemoglobinopathies were previously highly region-specific with
a predilection amongst African, Mediterranean, Middle-Eastern,
South-East Asian and Indian subcontinental groups. However,
widespread global migration has resulted in them affecting at least
5.2% of the global population. Annually there are over 332,000
affected conceptions or births, of which 275,000 are affected by SCD
requiring early diagnosis and prophylaxis (Modell 2008).
Sickle cell disease comprises a group of clinically significant
qualitative haemoglobin (Hb) disorders, in which the sickle gene is
inherited from at least one parent. The sickle mutation itself is the
result of a single base change (GAT→ GTT) in the sixth codon of exon
1 of the β-globin gene on short arm of chromosome 11, responsible
for the synthesis of the β-globin polypeptide of the Hb molecule
(α2β2). This change, in turn, results in replacement of the normal
glutamic acid with valine at position 6 of the β-globin chain and the
formation of sickle Hb. Sickle cell anaemia (SCA) is the homozygous
state, where the sickle gene is inherited from both parents. Other
sickle cell disorders result from the co-inheritance of the sickle cell
gene with the gene of other abnormal haemoglobin such as Hb
C, Hb D or HbO-Arab, giving rise to Hb SC disease, Hb SD disease
or Hb SO-Arab disease respectively. Moreover, the co-inheritance
of the sickle gene with thalassaemia genes (β0 or β+) results
in sickle-β0-thalassemia or sickle-β+-thalassaemia respectively.
In SCD, amino acid substitution causes HbS to polymerise
intracellularly when deoxygenated, thus changing the biconcave
discoid shape of red blood cells (RBCs) to sickle shapes. Sickling
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is precipitated by hypoxia, extreme temperatures, dehydration,
physical or emotional stress, menstruation and infection. The
sickled cells tend to have a shorter survival rate and plug vessels
in microcirculation leading to acute syndromes such as vasoocclusive crises (VOCs), sickle chest syndrome, aplastic crisis and
sequestration crisis; in the long term these are followed by chronic
organ damage (Fonseca 2007; Ingram 1957).
Clinical features of SCD include pain episodes, anaemia of variable
severity, organ damage and infection. Pain, however, is the
hallmark of SCD in general and SCA in particular and it is the most
important aspect of its clinical picture. All body organs are affected,
or are at risk of being affected, by SCD. The complications of most
major organs such as the brain, lungs, liver and kidney are relatively
well known and described in the literature. Treatment of dental
complications, however, has not been well addressed. Common
dental complications described in SCD include caries or cavities,
tooth hypomineralisation, orofacial pain, neuropathy, facial
swelling, pallor of oral mucosa, malocclusions, infections, pulpal
necrosis, cortical erosions, medullary hyperplasia and abnormal
trabecular spacings (Andrews 1983; Ballas 2014; Demirbas Kaya
2004; Fonseca 2007; Friedlander 1980; Mendes 2011; Scipio 2001;
Soni 1966; Taylor 1995). Studies have shown that individuals with
SCD have a greater risk of developing a general or dental infection,
commonly of unknown origin, as compared to controls; and these
dental infections could, in turn, in some cases be responsible
for precipitating sickle cell crises (O'Rourke 1990; Rada 1987).
Most providers know that dental complications such as infections
(gingivitis, periodontitis) and caries are factors that precipitate
VOCs. Dental infection through inflammatory mediators could
potentially trigger or exacerbate an already existing crisis leading to
increased hospital admissions (Laurence 2013). Providing access to
basic dental evaluation and treatment to adults with SCD resulted
in a clinically significant decrease in days hospitalized (Whiteman
2019).

Description of the intervention
Dental treatment for people with SCD should be designed
keeping in mind both their general health and the possible
impact of the dental procedures on their pre-existing systemic
condition. Prophylactic antibiotics are administered to prevent the
precipitation of VOCs or systemic infections as a result of dental
infections or surgical treatment procedures. Local anaesthetic,
conscious sedation, anxiolytics and sedatives to alleviate anxiety
are also used to avoid the precipitation of stress or pain-related
crises. Antidepressants, anticonvulsants and clonidine are used for
treating neuropathic pain (Fonseca 2007; Piccin 2008). For dental
procedures requiring intravenous sedation or general anaesthesia,
individuals are referred to hospitals with haematology expertise
and care is taken to keep the person well-hydrated and warm,
with oxygen therapy administered during and immediately after
the procedure. To correct malocclusion, orthodontic treatment
is carried out using light forces and increased periods of rest
during tooth movement, while monitoring bone response, pulpal
health and the systemic condition (Fonseca 2007; Rinchuse 2007;
Zahrowski 2009).

How the intervention might work
Splenic function is reduced in people with SCD, thus reducing their
immunity especially against encapsulated bacteria and increasing
their susceptibility to infection. Vaccinations against Pneumococcus
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pneumoniae can prevent the most frequent systemic complications
in these individuals. By the same rationale, antibiotic prophylaxis
before invasive dental surgical procedures is recommended to
prevent local or systemic infections and the precipitation of crises
in people with SCD. Conscious sedation, prescription of anxiolytics
and scheduling of dental appointments during chronic phases may
alleviate stress and prevent treatment-related sickle cell crises.
Orthodontic treatment is carried out using light forces and with
appropriate intervals of rest in order to avoid or minimize pain,
crises or infections during the procedure (Alves 2006).

METHODS

Why it is important to do this review

Types of interventions

Oral health issues or dental problems can no longer be considered
as isolated, random, mutually exclusive occurrences, but instead
need to be seen as an integral part of a complex holistic
physiological apparatus, where dysfunction in one system could
simultaneously be a cause as well as an effect of disturbance
in other intricately linked systems (Wison Schaeffer 1999). A lack
of understanding of this intimate relationship between oral and
general health among lay and medical people alike has led to
the exclusion of oral health as an important traditional clinical
indicator of general health and well-being. This is prominently
observed among people with special needs and medically
compromised conditions (like SCD) who are not only predisposed
to dental pathologies, but whose treatment also needs special
consideration. This results in many of these people being refused
treatment by dentists due to fear of trans- and post-operative
complications which they are unable or unequipped to deal
with. This could also be attributed to lack of clinical guidelines,
awareness and training or sufficient information, research or data
in the literature to enable healthcare providers to handle such cases
confidently and successfully (Laurence 2006; Passos 2012).

We planned to consider any study which included one or more of
the following interventions being compared with either placebo, no
treatment or an alternative treatment in the treatment of dental
complications.

Haemoglobin disorders, having lost their regional specificity, are
now a global concern. In poorer countries, improved hygiene,
nutrition and public health ensure reduced levels of infant
and childhood mortality, which means more infants with SCD
are surviving and presenting for treatment later in life. This
poses a challenge to public health resources and the expertise
of the medical community in handling and treating them,
prompting the issue to be labelled as an "emerging global health
burden" (Edwards 2005; Reisine 1985; Weatherall 2010). It is the
intention of this review to comprehensively explore the literature
and look for clinically useful evidence for the treatment of dental
complications and thus improve the oral health-related quality of
life (OHQoL) of people with SCD. This is an update of a previously
published review (Mulimani 2016).

OBJECTIVES
The main objectives of this review are to assess methods to treat
dental complications in people with SCD. The terminology 'dental
complications' is used to represent all oral infections, diseases and
conditions affecting the teeth, jaws, orofacial region and associated
structures, such as dental caries, periodontal disease, odontogenic
infections, osteomyelitis, cellulitis, craniofacial deformities and
malocclusion.

Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs.
Types of participants
All children and adults diagnosed with SCD irrespective of
phenotype, severity, age, gender and ethnic origin.

1. Management of dental pain using analgesics and alternative
techniques, e.g. acupressure, relaxation and Reiki.
2. Prevention of sickle cell crises during treatment (using preoperative analgesics, anxiolytics, conscious sedation and
prophylactic antibiotics).
3. Application of light forces, non-extraction mechanics and
modification of treatment according to bone and systemic
conditions during orthodontic therapy.
4. Early intervention and minimally invasive techniques for caries
management.
Types of outcome measures
Primary outcomes
1. Resolution or reduction in the severity of the condition (as
measured by)
a. decayed, missing, filled teeth (DMFT) index, radiographic
changes, salivary acid or streptococcus mutans levels for
dental caries
b. gingival or plaque indices, probing depth, bone level for
periodontal diseases
c. change in teeth or jaw positions, cephalometric analysis,
malocclusion indices (in case of malocclusions and
craniofacial deformities)
d. visual analogue scale, dichotomy scale or Likert scale for pain
assessment
e. any other relevant measure reported
Secondary outcomes
1. Adverse incidents consequent to treatment, e.g. systemic
infections, impairment or loss of oral function, iatrogenic
damage during treatment like pulpal necrosis, root resorption or
bone loss
2. Sickle cell crises due to dental complications in individuals with
SCD
3. Health service utilisation
a. frequency of emergency department visits and hospital
admissions
b. duration of hospitalisations
c. consultations with practitioners
4. Quality of life (physical and social function, ability to fulfil roles,
life satisfaction) as measured using a validated scoring system
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such as Health Status Survey Short Form (SF-36), the Profile of
Mood Status (POMS), Child Health Questionnaire-Parent Report
Form or any other
5. Economic effects (e.g. loss or change of job, number of days off
work or school, treatment cost)

Search methods for identification of studies

Cochrane Database of Systematic Reviews

We contacted haematologists, experts in different fields of
dentistry, organizations and researchers working in this field.
We also contacted pharmaceutical companies for information on
unpublished and ongoing studies.

Data collection and analysis

We attempted to identify all relevant studies regardless of language
and status of publication.

No studies were available for inclusion. The following methods will
be employed should studies be included in future updates of this
review.

Electronic searches

Selection of studies

We searched for relevant studies from the Cystic Fibrosis
and Genetic Disorders Group's Haemoglobinopathies Trials
Register using the term: dental AND (sickle cell disease OR
haemoglobinopathies general).

Two review authors (PM, SB) will independently assess for inclusion
all the potential studies identified as a result of the searches. We
will resolve any disagreement through discussion or, if required, we
will consult a third person (ABL).

The Haemoglobinopathies Trials Register is compiled from
electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated each new issue of The Cochrane
Library) and weekly searches of MEDLINE. Unpublished work
is identified by searching the abstract books of five major
conferences: the European Haematology Association conference;
the American Society of Hematology conference; the British Society
for Haematology Annual Scientific Meeting; the Caribbean Health
Research Council Meetings; and the National Sickle Cell Disease
Program Annual Meeting. For full details of all searching activities
for the register, please see the relevant section of the Cochrane
Cystic Fibrosis and Genetic Disorders Group Module.

We will include studies published only in abstract form if they
otherwise satisfy the review's inclusion criteria. We will contact the
authors of such studies if we require any additional information.

Date of latest search: 01 August 2019.
We also searched PubMed (www.ncbi.nlm.nih.gov/pubmed) and
Google Science (scholar.google.com/)
Date of latest search: 07 November 2019.
We also searched the following registries of ongoing clinical studies
from date of inception for evidence of unpublished studies and
protocols of published studies:
• ClinicalTrials.gov (ClinicalTrials.gov);
• WHO International Clinical Trials Registry Platform
(www.who.int/ictrp/search/en/);
• Literature in the Health Sciences in Latin America and the
Caribbean database (LILACS) (lilacs.bvsalud.org/en/);
• African Index Medicus (AIM 2002) (indexmedicus.afro.who.int/)
• Index Medicus for South East Asia Region (imsear.hellis.org/);
Medicus
for
the
Eastern
Mediterranean
• Index
Region
(www.emro.who.int/information-resources/imemr/
imemr.html);
• Indexing of Indian Medical Journals (www.indmed.nic.in/).
For more details of the individual search strategies, please refer to
the appendices (Appendix 2).
Date of latest search: 07 November 2019.
Searching other resources
We intended to scrutinize the reference lists of the identified
studies for additional citations and also to cross-check
references from any obtained studies to identify more studies.

Data extraction and management
We will design a form to record any extracted data from eligible
studies. Two review authors (PM, LK) will independently extract the
following information from any included studies.
1. Methods: study design; total duration of study; study location;
study setting; withdrawals; and date of study.
2. Participants: number enrolled; mean age or age range; gender;
severity of condition; diagnostic criteria if applicable; inclusion
and exclusion criteria.
3. Interventions: description of intervention; comparison;
duration; intensity; content of both intervention and control
condition; and co-interventions.
4. Outcomes: description of primary and secondary outcomes
specified and collected, and at which time points reported.
5. Notes: funding for trial, and notable conflicts of interest of trial
authors.
We will resolve discrepancies through discussion or, if required, we
will consult a third or fourth person (SB, ABL). We will enter the data
into the Review Manager software and check for accuracy (RevMan
2014). When information regarding any of the above is unclear, we
will attempt to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Two review authors (PM, ABL) will independently assess the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2017).
We will resolve any disagreement by discussion or by involving a
third assessor (LK).
1. Random sequence generation (checking for possible selection
bias)
For each included study, we will describe the method used to
generate the allocation sequence in sufficient detail to allow an
assessment of whether it should produce comparable groups. We
will assess the method as:
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• low risk of bias (any truly random process, e.g. random number
table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);
• unclear risk of bias.

• high risk of bias (e.g. numbers or reasons for missing
data imbalanced across groups; 'as treated' analysis done
with substantial departure of intervention received from that
assigned at randomisation);
• unclear risk of bias.

2. Allocation concealment (checking for possible selection bias)

In case of missing data we will take the following steps:

For each included study, we will describe the method used to
conceal the allocation to interventions prior to assignment and will
assess whether this allocation could have been foreseen in advance
of, or during recruitment, or changed after assignment. We will
assess the methods as:

• if possible, contact the original investigators to request missing
data;
• make explicit any assumptions we make to deal with missing
data, for example, if we assume that the data are missing at
random, or if we assume that missing data have a particular
value such as a poor outcome;
• perform sensitivity analyses to assess how sensitive results are
to reasonable changes in the assumptions that are made;
• address the potential impact of missing data on the findings of
the review in the 'Discussion' section.

• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
• unclear risk of bias.
3. Blinding
3.1. of participants and personnel (checking for possible performance
bias)

For each included study, we will describe the methods used, if any,
to blind study participants and personnel from knowledge of which
intervention a participant received. We will consider that studies
are at low risk of bias if they were blinded, or if we judge that the
lack of blinding would be unlikely to affect results. We will assess
blinding separately for different outcomes or classes of outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
3.2. of outcome assessment (checking for possible detection bias)

For each included study, we will describe the methods used, if any,
to blind outcome assessors from knowledge of which intervention a
participant received. We will assess blinding separately for different
outcomes or classes of outcomes. We will assess methods used to
blind outcome assessment as:
• low risk of bias;
• high risk of bias;
• unclear risk of bias.
4. Incomplete outcome data (checking for possible attrition bias
due to the amount, nature and handling of incomplete outcome
data)
For each included study and for each outcome or class of outcomes,
we will describe the completeness of data including attrition and
exclusions from the analysis. We will state whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to
outcomes. Where sufficient information is reported, or can be
supplied by the study authors, we will re-include missing data in the
analyses which we undertake. We will assess methods as:

5. Selective reporting (checking for reporting bias)
For each included study, we will describe how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
6. Other bias (checking for bias due to problems not covered by
(1) to (5) above)
For each included study, we will describe any important concerns
we have about other possible sources of bias. We will assess
whether each study was free of other problems that could put it at
risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
7. Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2017).
With reference to points 1 to 6 above, we will assess the likely
magnitude and direction of the bias and whether we consider it is
likely to impact on the findings. We will explore the impact of the
level of bias through undertaking sensitivity analyses
Measures of treatment effect
For dichotomous data (e.g. adverse effects), we will present results
as a summary risk ratio (RR) with 95% confidence intervals (CIs).

• low risk of bias (e.g. no missing outcome data; missing outcome
data balanced across groups);
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For continuous data (e.g. number of decayed, missing or filled
teeth), we will use the mean difference (MD) and 95% CIs if
outcomes are measured in the same way between studies. We
will use the standardised mean difference (SMD) to combine
studies that measure the same outcome, but use different units of
measurement.
We will calculate the events occurring more than once per person
as the number of counts and treated in the same way as continuous
outcome data. We will present the MD and compare the difference
in the mean number of events (standardized to a unit time period)
experienced by participants in the intervention group compared
with participants in the control group (Deeks 2017).
Unit of analysis issues
We will include cluster-randomised studies in the analyses along
with individually randomised studies. We will adjust their sample
sizes by methods using an estimate of the intra-cluster correlation
co-efficient (ICC) derived from the study (if possible), or from
another source. If we use ICCs from other sources, we will report
this and conduct sensitivity analyses to investigate the effect of
variations in the ICC. If we identify both cluster-randomised studies
and individually randomised studies, we plan to synthesise the
relevant information. We will consider it reasonable to combine
the results from both types of study if there is little heterogeneity
between the study designs and the interaction between the
effect of intervention and the choice of randomisation unit is
considered to be unlikely. We will also acknowledge heterogeneity
in the randomisation unit and perform a separate meta-analysis.
Therefore, we will perform the meta-analysis in two parts.
Dealing with missing data
For included studies, we will note levels of attrition. We will explore
the impact of including studies with high levels of missing data in
the overall assessment of treatment effect by using a sensitivity
analysis. For all outcomes, we will carry out analyses (as far as
possible) on an intention-to-treat basis, i.e. we will attempt to
include all participants randomised to each group in the analyses,
and all participants will be analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each study
will be the number randomised minus any participants whose
outcomes are known to be missing. We will exclude studies with
more than 20% missing data. We will also perform sensitivity
analyses to assess how sensitive results are to reasonable changes
in the assumptions that we make.
Assessment of heterogeneity
We will assess methodological heterogeneity by examining the risk
of bias of any included trial. We will assess statistical heterogeneity
among studies by visually inspecting the forest plots and using
the Chi2 test and I2 statistic for heterogeneity with a statistical
significance level of P value < 0.10. For the interpretation of the I2
values, we will use the following guidelines (Higgins 2017):
•
•
•
•

0% to 40%: might not be important;
30% to 60%: may represent moderate heterogeneity;
50% to 90%: may represent substantial heterogeneity;
75% to 100%: considerable heterogeneity.

Cochrane Database of Systematic Reviews

If we identify substantial heterogeneity, we will report it and explore
possible causes by subgroup analysis.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will
investigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually and if this
suggests there is asymmetry, we will perform exploratory analyses
to investigate this as detailed in the Cochrane Handbook for
Systematic Reviews of Interventions (Sterne 2017).
Data synthesis
We will carry out statistical analysis using the Review Manager
software (RevMan 2014). We will use a fixed-effect meta-analysis
for combining data where it is reasonable to assume that studies
are estimating the same underlying treatment effect, i.e. where
studies are examining the same intervention, and the study
populations and methods are judged sufficiently similar. If there
is clinical heterogeneity sufficient to expect that the underlying
treatment effects will differ between studies, or if substantial
statistical heterogeneity is detected and a pooled treatment effect
across studies is still considered clinically meaningful, we will use
a random-effects meta-analysis to produce an overall summary
and discuss the clinical implications of treatment effects differing
between studies. If we use a random-effects analysis, we will
present the results as the pooled treatment effect with 95% CIs and
the estimates of I2. If the pooled treatment effect is not clinically
meaningful, we will not combine studies.
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it using
subgroup analyses. We will consider whether an overall summary
is meaningful, and if so we will use a random-effects analysis to
produce it. We plan to carry out the following subgroup analyses:
• male versus female participants;
• different ages paediatric (up to 18 years of age) versus adult (18
years and over);
• different types of SCD.
We will assess subgroup differences using interaction tests
available within the Review Manager software (RevMan 2014). We
will report the results of the subgroup analyses quoting the Chi2 test
and P value, and the interaction test I2 value.
Sensitivity analysis
We will perform sensitivity analyses for aspects of the review that
might affect the results; for example, where there is a risk of bias
associated the included studies. We will undertake analysis of the
primary outcome separately for studies with a low risk of bias
and a high or unknown risk of bias for allocation concealment.
We will explore the impact of including studies with high levels
of missing data in the overall assessment of treatment effect and
also to assess how sensitive results are to reasonable changes in
the assumptions that are made on missing data. We will also carry
out a sensitivity analysis to explore the effects of random-effects
analyses for outcomes with statistical heterogeneity. We will also
conduct sensitivity analyses to investigate the effect of variations in
any ICCs we have used.
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Summary of findings table
We will create a 'Summary of findings' table for each comparison
using the following outcomes.
1. Resolution or reduction in the severity of the condition
2. Adverse incidents consequent to treatment
3. Health service utilisation
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence as it relates
to the studies which contribute data to the meta-analyses
for the prespecified outcomes. We will use methods and
recommendations described in section 8.5 and chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions using
GRADEpro software (Higgins 2017; Schünemann 2017). We will
justify all decisions to down- or upgrade the quality of studies
using footnotes and we will make comments to aid the reader's
understanding of the review where necessary.

RESULTS
Description of studies
Results of the search
The searches (last updated in August and November 2019) did
not identify any RCTs or quasi-RCTs eligible for inclusion in this
Cochrane Review (nor any that were potentially eligible); we were
not able to identify any ongoing studies.

Risk of bias in included studies
The searches did not identify any RCTs or quasi-RCTs eligible for
inclusion in this Cochrane Review (nor any that were potentially
eligible).

Effects of interventions
The searches did not identify any RCTs or quasi-RCTs eligible for
inclusion in this Cochrane Review (nor any that were potentially
eligible), nor were we able to identify any ongoing trials.

DISCUSSION
Summary of main results
Despite undertaking an extensive search of the literature (electronic
searching, handsearching and identifying ongoing trials) for the
original review, no RCTs were identified which met the inclusion
criteria. Our updated search results of all databases in 2019 were
also not able to identify any new trials potentially eligible for
inclusion in this review.

Potential biases in the review process
This Cochrane Review contains no studies and as such, no risk
of bias could be evaluated. it is possible that trials with negative
results may have remained unpublished. In spite of the extensive
search carried out, no RCTs were available for inclusion. The main
limitation of this Cochrane Review is the paucity of evidence for
treatment of dental complications in people with SCD.

Cochrane Database of Systematic Reviews

Agreements and disagreements with other studies or
reviews
Due to the absence of evidence from RCTs or quasi-RCTs, we were
unable to compare our results with other published systematic
reviews or excluded studies. During our search, we did identify
a small body of mid-level evidence derived from observational
studies such as cohort, case-control and cross-sectional sectional
studies, but most of these report incidences or prevalences of
dental diseases and their impact on people with SCD compared to
healthy controls and do not investigate any intervention for treating
these complications. Furthermore the bulk of the evidence in this
area is of low level, derived mostly from retrospective studies, case
reports and expert opinion articles which consist predominantly
of descriptive narrations of the pathological changes in the oraldental-craniofacial region, general principles of treatment and
specific interventions in cases encountered. A condensed summary
of available information derived from these sources follows.
Two studies recommended that if individuals are experiencing
a vaso-occlusive crisis, only emergency relief of pain and
infection is indicated. Infections should be treated with antibiotics
and definitive treatment postponed until the crisis subsides
(Hammersley 1984; Rouse 1979). A retrospective study reported
successfully performing outpatient procedures without any
complications in people with SCD by administering 2% lignocaine
with 1:100,000 epinephrine (Stanley 2013). Acetaminophen or
codeine were recommended for post-operative pain control,
but aspirin was not recommended due to its possible adverse
effect on platelet function resulting in increased bleeding, acidbase balance and bone marrow suppression (Smith 1986).
In cases of osteomyelitis in the posterior mandibular region,
treatment may include sequestrectomy, curettage, debridement,
corticotomy and resection of mandible and affected muscles
with appropriate antibiotic coverage and following the surgical
principles recommended for people with SCD (Hammersley 1984;
Lawrenz 1999; Shroyer 1991). The 2014 evidence-based expert
panel report on SCD recommends using red blood cell transfusion
to bring preoperative haemoglobin levels to 10 g/dL prior to any
surgical procedures involving general anaesthesia (Yawn 2014).
Avascular pulpal necrosis in clinically intact teeth was a common
finding in people with SCD; hence, a routine evaluation of pulp in
clinically intact teeth was recommended (Costa 2013). Root canal
therapy must be carried out to satisfactory technical standard and
antibiotic prophylaxis may be required; this therapy may also cause
a sickle cell crisis (Gregory 1994).
A study has reported that 30.1% of individuals with SCD had
indications for mandatory orthodontic treatment as compared to
only 2.7% of the controls (Costa 2013). Orthodontic treatment
in people with SCD was considered to be elective (Sams 1990);
however successful treatment with fixed appliances in conjunction
with extractions and extraoral orthopedic appliances has been
reported (Oluwatosin 2009; Pithon 2011).
Prevention of dental complications is considered the best approach
in people with SCD. It is recommended that periodic dental
screening should be provided as part of their general physical
examination. Incorporating fluorides, maintaining oral hygiene,
routine dental visits and treating dental issues as soon as they are
detected are measures which can reduce complications (Demas
1988; Javed 2013; Rouse 1979).
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This systematic review did not identify any randomised controlled
trials (RCTs) or quasi-RCTs to guide treatment of dental
complications in people with sickle cell disease (SCD). Accordingly,
we are unable to evaluate the effects of any interventions. In
the absence of high-quality evidence, clinicians need to use
their clinical judgement and refer to lower-level evidence (e.g.
observational studies, case reports, expert opinion) for selecting
the best and most suitable form of intervention for treating the
dental complications in people with SCD.

Implications for research
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adequately powered RCTs to assess the effectiveness of treatments
for dental complications in people with SCD.
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APPENDICES
Appendix 1. Glossary of terms

Term

Explanation

aplastic crisis

temporary cessation of red cell production

exon

portion of a gene that codes for amino acids

gingivitis

inflammation of the gingiva as a response to bacterial plaque on adjacent teeth

homozygous

having identical pairs of genes for any given pair of hereditary characteristics

hypomineralization

a condition affecting the enamel of the permanent teeth and characterized by a deficiency of minerals; normal enamel is white and very hard, but hypomineralized enamel is creamy, yellow or
brown in colour and is chalky in texture. As a result teeth look different in appearance, they also
undergo wear and are at higher risk of developing decay

hypoxia

this is when the body doesn't have enough oxygen

intracellular

within a cell

malocclusion

a 'poor bite', misaligned teeth between the top and bottom jaws

morphology

the form and structure of an organism or any of its parts

odontogenic

of, or relating to, the formation and development of teeth

oral mucosa

the mucous membrane lining the inside of the mouth, including lining on the gums, the palate, the
lip, the cheek, the floor of the mouth and other structures

orofacial

relating to the mouth and face

osteomyelitis

inflammation of the bone marrow and adjacent bone

periodontitis

a serious gum infection that damages the soft tissue and destroys the bone that supports your
teeth; if inflammation of the gum tissue (gingivitis) is not treated periodontitis can develop

polymerize

a process through which relatively small molecules, called monomers, combine chemically to produce a very large chainlike or network molecule, called a polymer
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(Continued)

sequestration crisis

a condition affecting people with sickle cell anaemia which results from the trapping of large
amounts of red cells in the spleen and sometimes in the liver so they are withdrawn from the blood
in circulation leading to a sharp drop in haemoglobin levels

vaso-occlusive

relating to, resulting from, or caused by occlusion of a blood vessel

Appendix 2. Multiple databases search strategy

SEARCH SITE

Date of search:
From inception to

Google Scholar

07 November 2019

Type of
Search

Keywords used

Results

Relevant RCTs
from results

Advanced

allintitle: sickle dental trial

0

0

allintitle: sickle trial

372

0

allintitle: sickle dental

77

0

sickle dental

0

0

Sickle oral

0

0

Sickle cell AND dental AND treatment

0

0

Sickle cell AND dental oral

0

0

Sickle cell AND dental

1

0

Sickle cell AND dental AND treatment

1

0

(scholar.google.com/)

WHO ICTRP

07 November 2019

Basic

(www.who.int/ictrp/search/
en/)
07 November 2019

Advanced

Sickle cell AND oral AND treatment

ClincialTrials.gov

07 November 2019

Basic

"sickle cell" AND "dental"

1

0

(ClinicalTrials.gov)

07 November 2019

Advanced

Sickle cell, dental treatment

1

0

LILACS

07 November 2019

Basic

Sickle dental

26

0

Sickle dental trial

0

0

Sickle cell AND dental treatment

113

0

Sickle cell AND dental AND trial

3

0

Sickle cell AND dental

0

0

Sickle and dental

0

0

“sickle cell” and “dental”

0

0

(lilacs.bvsalud.org/en/)
07 November 2019

African Index Medicus

07 November 2019

Advanced

Basic

(indexmedicus.afro.who.int/)
07 November 2019

Advanced
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IMSEAR

07 October 2019

Basic

“sickle” and “randomized controlled trial”

392

0

07 October 2019

Basic

Sickle cell AND dental

0

0

Sickle and dental

0

0

(imsear.hellis.org/)
IMEMR
(www.emro.who.int/information-resources/imemr/imemr.html)
IndMED

07 October 2019

Advanced

“sickle cell” and “dental”

0

0

03 March 2016

Basic

Sickle AND dental

2

0

07 October 2019

Advanced

Sickle cell AND dental

209

0

(www.indmed.nic.in/)
Pubmed
(www.ncbi.nlm.nih.gov/pubmed)

WHAT'S NEW

Date

Event

Description

25 November 2019

New search has been performed

A search of the Cochrane Cystic Fibrosis and Genetic Disorders
Review Group's Haemoglobinopathies Trials Register did not
identify any new references potentially eligible for inclusion in
the review.
A search of the multiple databases did not not identify any new
studies potentially eligible for inclusion in the review.

25 November 2019

New citation required but conclusions
have not changed

Since no new studies have been added to the review, our conclusions remain the same.
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